Bausch + Lomb Corporation reports developments across its global eye health business, including vision care, surgical devices and ophthalmic pharmaceuticals. Recurring updates cover contact lenses and lens care products, eye vitamins and redness-relief drops, dry eye and prescription ophthalmology brands, intraocular lenses, vitrectomy cutters and the Stellaris Elite Vision Enhancement System.
Company news also includes financial results and guidance, scientific presentations, R&D pipeline discussions, FDA 510(k) clearances, European product launches and sustainability programs such as ONE by ONE Recycling. Product-specific coverage frequently references Biotrue, LUMIFY, XIIDRA, MIEBO, PreserVision, INFUSE, ULTRA ONE DAY, enVista and Bi-Blade technologies.
Bausch + Lomb (BLCO) announced publication of a multinational survey examining dry eye symptoms, professional care and treatment experiences across five countries. The NESTS survey, conducted between February and April 2025, included 2,580 general-population respondents and 2,572 respondents with self-reported dry eye in separate cohorts across the United Kingdom, France, Germany, Poland and Saudi Arabia.
Across countries, 14–39% of general-population respondents reported regular dry eye, while 13–25% reported a health care professional diagnosis. Among respondents with self-reported dry eye, 41–58% experienced daily symptoms, and 30–39% reported worsening in the previous year. Most who had consulted a professional were not currently receiving doctor-directed treatment. Bausch + Lomb said the findings highlight opportunities for education and timely assessment.
Bausch + Lomb (BLCO) reported third-quarter 2026 revenue of $1.375 billion and raised its full-year revenue and adjusted earnings guidance. Revenue rose 7% year over year, or 8% excluding currency movements. GAAP net income attributable to the company was $32 million, versus a $28 million loss; basic and diluted earnings per share were $0.09 versus a $0.08 loss.
Vision Care revenue rose 5%, Surgical 9% and Pharmaceuticals 11%. Operating cash flow increased to $233 million from $137 million. Adjusted EBITDA, a non-GAAP earnings measure, reached $325 million versus $243 million, both including and excluding acquired research and development.
The company now expects 2026 revenue of $5.450–$5.550 billion, versus $5.440–$5.540 billion previously, and adjusted EBITDA excluding acquired research and development of $1.090–$1.140 billion, versus $1.025–$1.075 billion.
Bausch + Lomb (BLCO) appointed board chairman Thomas J. Appio interim chief executive officer, effective immediately, replacing departing CEO Brent Saunders. Appio will also remain CEO of parent company Bausch Health (BHC). Saunders and the Bausch + Lomb board mutually agreed on his departure.
Based on preliminary third-quarter results, both companies expect to raise full-year 2026 adjusted EBITDA excluding acquired in-process research and development guidance, a non-GAAP earnings measure. They attribute the expected increases to third-quarter business performance and anticipated better performance for the remainder of 2026. Additional details are due with third-quarter results on October 28. Bausch Health, excluding Bausch + Lomb, has delivered 13 consecutive quarters of year-over-year revenue and adjusted EBITDA growth under Appio.
Bausch + Lomb (BLCO) plans to begin its clinical development program for investigational oral dry AMD treatment BL1243 in 2027.
BL1243, also called tonabersat, is being developed for earlier-stage dry age-related macular degeneration, an eye disease. Following an FDA meeting, the company said it had greater clarity on the development path. The FDA supported, in principle, the proposed initial study design, which will examine how the medicine behaves in the body and assess safety.
Barring unexpected findings, initial study results are expected to support advancement into a Phase 2 study involving dry AMD patients who have not yet developed advanced retinal damage. Bausch + Lomb sees a potential oral treatment option for earlier-stage disease if development succeeds and approval is obtained; the meeting was not a treatment approval.
Bausch + Lomb (BLCO) will release its third-quarter 2026 financial results on Oct. 28 and host a call that morning. The conference call and live webcast begin at 8 a.m. ET to discuss results and provide a business update. Materials will be available on the company's Investor Relations website before the call.
Bausch + Lomb (BLCO) received European CE Mark approval for its next-generation SeeLyra femtosecond laser platform for ophthalmic surgery. SeeLyra is described as one of the most compact femtosecond systems, designed to provide precision and control in laser-assisted preparation for premium cataract, LASIK flap and corneal therapeutic procedures, while supporting efficient workflows in space-constrained operating rooms.
The platform integrates live swept source OCT for real-time depth visualization and precise positioning of laser cuts, and retains features from the prior VICTUS platform such as an intuitive user interface and broad procedural adaptability. Its compact, mobile design without a fixed patient bed allows flexible positioning, compatibility with existing beds and may improve patient comfort. SeeLyra will be available in Europe on a limited basis in the coming months, with wider availability expected in 2027, and Bausch + Lomb is pursuing approvals in additional markets, including the United States.
Bausch + Lomb (BLCO) reported new published real‑world research on its enVista Aspire and enVista Aspire toric intraocular lenses for cataract patients.
The multicenter retrospective case series included 84 patients and 141 eyes (88 enVista Aspire, 53 enVista Aspire toric). In the enVista Aspire group, 97.2% of eyes achieved monocular corrected distance visual acuity (CDVA) of 20/25 or better, 71.3% uncorrected distance (UDVA) of 20/25 or better, and 76.6% uncorrected intermediate (UIVA) of 20/32 or better. In the toric group, 94.9% of eyes reached CDVA 20/25 or better, 84.9% UDVA 20/25 or better, and 93% UIVA 20/32 or better. All subjects in both groups achieved binocular UIVA of 20/32 or better, and no serious adverse events were reported. The lenses use intermediate‑optimized optics designed to broaden depth of focus beyond standard monofocal IOLs.
Bausch + Lomb (NYSE/TSX: BLCO) released results from its 2026 (Peri)Menopause Survey of 402 peri-, menopausal and post-menopausal women, showing a large awareness gap between menopause and dry eye disease.
Only 14% recognized dry eye as a menopause-related symptom versus 79% for hot flashes, and 78% were surprised to learn of the connection. Among women with dry eye during these stages, 80% said the symptom came as a surprise, and many reported functional impacts: 58% had difficulty reading, 53% using screens, 26% driving and 17% experienced reduced productivity. Bausch + Lomb highlighted its broad dry eye portfolio and ongoing education efforts, directing women to KnowYourDryEye.com for information.
Bausch + Lomb (NYSE/TSX: BLCO) reported clinical data for two first-in-class ophthalmic candidates and outlined advancement plans. A Phase 2 trial of its dual-action dry eye eye drop, combining 5% lifitegrast and perfluorohexyloctane, did not meet the Day 29 primary endpoint versus lifitegrast alone, but a pre-specified Day 15 analysis showed a statistically significant tCFS improvement (p=0.0007). Based on this, the company will move the program into Phase 3 using Day 15 as the primary endpoint.
The TRPV1 antagonist BL1332 showed positive Phase 1b results in a capsaicin-induced ocular pain model, with a 5.5-point pain reduction versus vehicle at five seconds and markedly shorter pain duration (1.6 vs 37.8 seconds). BL1332 is in Phase 2 for post-surgical pain, with topline results expected in the coming months. According to Bausch + Lomb, estimated combined peak sales for the dry eye therapy and BL1332 are about $2.1 billion, assuming successful development and commercialization beyond 2028.
Bausch Health (NYSE: BHC) announced that its CEO, Thomas J. Appio, has been appointed to the board of directors of Bausch + Lomb (NYSE: BLCO), effective August 5, 2026. Bausch + Lomb is described as a key asset of Bausch Health.
Additional directors Robert J. Chersi, Laurence E. Paul, M.D., and Barbara J. Trebbi also joined the Bausch + Lomb board. They replace Steven Collis, Karen Ling, Thomas Ross and Andrew von Eschenbach, MD, who resigned without any stated disagreements with Bausch + Lomb. Bausch Health remains Bausch + Lomb’s largest shareholder, indirectly holding about 87% of its outstanding common shares, and requested these board changes in line with its ownership position.